Skip to main content
PMC home page
Springer logoLink to Springer
. 2015 May 12;31(6):1243–1249. doi: 10.1007/s10554-015-0664-4

Prognostic value of heart valve calcifications for cardiovascular events in a lung cancer screening population

Martin J Willemink 1,✉, Richard A P Takx 1, Ivana Išgum 2, Harry J de Koning 3, Matthijs Oudkerk 4, Willem P Th M Mali 1, Ricardo P J Budde 1,5, Tim Leiner 1, Rozemarijn Vliegenthart 4,6, Pim A de Jong 1
PMCID: PMC4486764  PMID: 25962863

Abstract

To assess the prognostic value of aortic valve and mitral valve/annulus calcifications for cardiovascular events in heavily smoking men without a history of cardiovascular disease. Heavily smoking men without a cardiovascular disease history who underwent non-contrast-enhanced low-radiation-dose chest CT for lung cancer screening were included. Non-imaging predictors (age, smoking status and pack-years) were collected and imaging-predictors (calcium volume of the coronary arteries, aorta, aortic valve and mitral valve/annulus) were obtained. The outcome was the occurrence of cardiovascular events. Multivariable Cox proportional-hazards regression was used to calculate hazard-ratios (HRs) with 95 % confidence interval (CI). Subsequently, concordance-statistics were calculated. In total 3111 individuals were included, of whom 186 (6.0 %) developed a cardiovascular event during a follow-up of 2.9 (Q1–Q3, 2.7–3.3) years. If aortic (n = 657) or mitral (n = 85) annulus/valve calcifications were present, cardiovascular event incidence increased to 9.0 % (n = 59) or 12.9 % (n = 11), respectively. HRs of aortic and mitral valve/annulus calcium volume for cardiovascular events were 1.46 (95 % CI, 1.09–1.84) and 2.74 (95 % CI, 0.92–4.56) per 500 mm3. The c-statistic of a basic model including age, pack-years, current smoking status, coronary and aorta calcium volume was 0.68 (95 % CI, 0.63–0.72), which did not change after adding heart valve calcium volume. Aortic valve calcifications are predictors of future cardiovascular events. However, there was no added prognostic value beyond age, number of pack-years, current smoking status, coronary and aorta calcium volume for short term cardiovascular events.

Keywords: Lung cancer screening, Heart valves, Calcifications, Computed tomography, Prognosis, Cardiovascular events

Introduction

Cardiovascular disease is one of the most important causes of death in heavy cigarette smokers [1]. Calcifications of the coronary arteries, aorta and heart valves are known predictors for cardiovascular events and can be quantified with electrocardiography (ECG) synchronized computed tomography (CT) [2–9].

Lung cancer screening studies such as the Dutch Belgian randomized lung cancer screening trial (NELSON) and the national lung screening trial (NLST) involve CT imaging of the chest without ECG synchronization [1, 10, 11]. These screening studies are aimed at detecting lung cancer, but they can also provide information about other diseases such as chronic obstructive pulmonary disease and cardiovascular disease [12, 13]. Despite the absence of ECG triggering, recent studies have shown that coronary and aortic calcifications can be quantified on lung cancer screening chest CT images and can provide prognostic information on future cardiovascular events [14–17]. Since smoking is not only a risk factor for lung cancer, but also for cardiovascular disease, these results could be beneficial for the effectiveness of chest CT screening in substantial smokers.

A previous study has shown that it is technically possible to detect and quantify cardiac valve calcifications on low-dose unenhanced non-triggered lung cancer screening CT images [18]. However, the prognostic value of heart valve calcifications for cardiovascular disease in heavily smoking men is unknown.

The aim of the current study was to assess the prognostic value of calcifications of the aortic valve and mitral valve/annulus for cardiovascular events in 3111 heavily smoking men without a history of cardiovascular disease, participating in the NELSON lung cancer screening trial.

Materials and methods

Study population

Heavily smoking or formerly smoking subjects without a history of cardiovascular disease who underwent a chest CT-scan as part of the NELSON screening trial (Clinical Trial Registration ISRCTN63545820) at the University Medical Centers of Groningen and Utrecht were included.

The NELSON trial was approved by the Dutch Minister of Health and the local Ethical Reseach Boards of the participating hospitals. The study population was recruited between September 2003 and April 2006. Questionnaires were sent to individuals living in four regions (Groningen, Utrecht, Haarlem, and Leuven) [10, 11]. The addresses of individuals aged between 50 and 75 were obtained from the population registries. Based on the questionnaires, 15,822 individuals with high lung cancer risk were included. Only individuals were included who had smoked 15 cigarettes or more per day during 25 years, or 10 cigarettes or more per day during 30 years, and were still smoking or had quit <10 years ago [10]. The study population was divided into a screening group of 7915 individuals who underwent four chest CT scans and a control group of 7907 individuals. Exclusion criteria included not enough cardiopulmonary reserve to undergo surgery, current or past renal cancer, melanoma or breast cancer, and diagnosis of lung cancer within 5 years before filling in the questionnaire and lung cancer that is still treated, and a chest CT scan within 1 year before filling out the questionnaire [11].

For the current study, subjects from the screening groups of two centers (Groningen and Utrecht) were included for efficiency reasons. Since only 89 women were present in this sample, women were excluded. All subjects underwent a baseline chest CT scan between January 2004 and December 2007.

Image acquisition

Non-contrast enhanced images of the chest were acquired without ECG gating on 16-slice CT systems (Brilliance 16P or Mx8000 IDT, Philips Healthcare, Best, The Netherlands or Sensation 16, Siemens Healthcare, Forchheim, Germany). Low radiation dose protocols were used with a collimation of 16 × 0.75 mm, a tube voltage of 120 kV for participants weighing less than 80 kg or 140 kV for participants weighing 80 kg or more. Tube current settings varied based on hardware and participant weight.

Data collection

Information about non-imaging predictors (age, smoking status and pack years) was collected from the baseline NELSON questionnaires. Calcium volume of the aorta and coronary arteries were previously obtained using an in-house developed software package as described by Isgum et al. [19, 20] and Mets et al. [15]. This software package was also used in the current study for quantification of aortic and mitral valve calcifications. Calcium volume of the aortic valve and the mitral valve/annulus were quantified manually. Since it is very difficult to differentiate the mitral annulus from the mitral valve on a non-contrast enhanced low radiation dose non-gated chest CT, the values were taken together as total mitral valve calcification. In the remainder, ‘mitral valve calcification’ refers to calcification of both valve and annulus (if applicable). The volume (mm3) of regions with a density of 130 Hounsfield units or more was determined. If no calcifications were present, the volume was set at 0 mm3. A previous study by van Hamersvelt et al. [18] has shown that the inter-observer and inter-examination variability of cardiac valve measurements is sufficient to allow for longitudinal studies, especially for the aortic valve.

The outcome variable was the occurrence of cardiovascular events, which was obtained by linkage of subjects with the National Death Registry and the National Registry of Hospital Discharge Diagnoses. Both fatal and nonfatal cardiovascular events that occurred between January 1995 and January 2008 were included. Cardiovascular events were classified according to the World Health Organization’s International Classification of Diseases [21]. Cardiovascular events included hypertensive disease, ischemic heart disease, heart failure, diseases of arteries, arterioles and capillaries, cerebrovascular disease, or other heart disease. Individuals with a history of cardiovascular disease, defined as a hospitalization for a cardiovascular event in the 10 years before the CT, were excluded. If a subject was admitted to a hospital for a cardiovascular disease and died later on due to a cardiovascular disease, cardiovascular death was chosen as the outcome value. If a subject was admitted multiple times to a hospital for a cardiovascular disease, the diagnosis at first discharge was used.

Data analysis

Missing data were imputed using single linear regression imputation since less than 5 % of data were missing and missing data were random. Baseline characteristics were compared between individuals with a cardiovascular event and individuals without a cardiovascular event using the Mann–Whitney U test (continuous data) or the Chi square test (frequency data). Calcification volumes of the aorta and coronaries and the aortic and mitral valves were truncated at the 99th percentile as previously described [15]. Furthermore, the number of pack years was truncated at 50 years since higher numbers of pack years did not increase cardiovascular risk [15]. In order to perform a Cox proportional hazards (PH) regression analysis, the PH assumption was checked by the Schoenfield residuals. A multivariable prediction model was made for cardiovascular risk using Cox PH regression analysis. Based on this prediction model the hazard ratios (HRs) of the predictors were calculated with 95 % confidence intervals (CI). Subsequently, a bootstrap analysis was performed to correct for over-optimism. An age-adjusted survival curve was evaluated by presence and absence of aortic valve calcifications.

Concordance-statistics (c-statistics) were calculated to evaluate the discriminative capacity between a subject with and a subject without a cardiovascular event [22, 23].

Data are presented as medians (first quartile–third quartile) unless otherwise stated. Statistical analyses were performed using R version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS Statistics version 20 (SPSS Inc, Chicago, Illinois, The United States). Statistical testing was two-sided, and a p value below 0.05 was considered statistically significant.

Results

In total 3111 men were included, 1620 from the region of Groningen and 1491 from the region of Utrecht. Detailed characteristics of the individuals are listed in Table 1. In total 0.13 % of data for 6 variables was missing. Therefore, missing data were imputed using single linear regression imputation. In total 186 individuals (6.0 %) developed a cardiovascular event during a follow-up of 2.9 (Q1–Q3, 2.7–3.3) years. Aortic valve calcifications were present in 657 individuals (21.1 %) of whom 59 individuals (9.0 %) developed a cardiovascular event. An example image of a subject with a calcification in the aortic valve is displayed in Fig. 1. Mitral valve calcifications were present in 85 individuals (2.7 %) of whom 11 developed a cardiovascular event (12.9 %).

Table 1.

Demographic characteristics of the 3111 lung cancer screening participants

Variable No event (N = 2925) CV event (N = 186) P-value
Age (years) 59.2 (55.9–63.3) 60.8 (57.1–65.1) 0.000*
Length height (cm) 179.0 (174.8–183.0) 178.0 (175.0–183.0) 0.560*
Number of current smokers (%) 1658 (56.7 %) 128 (68.8 %) 0.000**
Pack years 38.0 (28.0–46.2) 38.7 (29.7–49.5) 0.019*
Coronary calcification volume (mm3) 126.4 (6.8–528.6) 590.2 (152.1–1441.4) 0.000*
Aortic calcification volume (mm3) 419.4 (74.0–1365.9) 1352.7 (301.7–3128.6) 0.000*
Number of individuals with aortic valve calcifications 598 (20.4 %) 59 (31.7 %) 0.000**
Aortic valve calcification volume (mm3) 96.3 (39.7–235.4) 179.1 (71.6–387.1) 0.002*
Number of individuals with mitral valve/annulus calcifications 74 (2.5 %) 11 (5.9 %) 0.006**
Mitral valve/annulus calcification volume (mm3) 140.8 (54.4–357.1) 216.9 (44.5–356.4) 0.977*
Open in a new tab

Values are medians (first quartile–third quartile) or numbers (percentages)

Significant values are marked bold

*P-value based on Mann–Whitney U test

**P-value based on Chi square test

Fig. 1.

Fig. 1

Open in a new tab

Subject with a calcified aortic valve (a), and a subject with coronary and mitral annulus calcifications (b) Ao aorta, AoV aortic valve, PA pulmonary artery, RA right atrium, LV left ventricle, MA mitral annulus, LAD left anterior descending coronary artery

The plotted Schoenfeld residuals showed no relevant deviations and thus the PH assumption was not violated and therefore a multivariable Cox PH regression analysis could be performed. For each variable the HR was calculated with 95 % CI. Bootstrap analysis resulted in an over-optimism correction factor of 0.988. Corrected HRs with 95 % CI are listed in Table 2. Significant predictors included current smoking status [HR for not smoking of 0.82 (0.72–0.93)], coronary calcium volume per 500 mm3 [HR of 1.11 (95 % CI, 1.06–1.16)], aortic calcium volume per 500 mm3 [HR of 1.02 (95 % CI, 1.00–1.04)] and aortic valve calcium volume per 500 mm3 [1.46 (95 % CI, 1.09–1.84)]. Mitral valve calcification volume was not a significant predictor with an HR of 2.74 [95 % CI, 0.92–4.56] per 500 mm3.

Table 2.

Effects of predictors on 3 year risk on cardiovascular events (N = 3111)

Predictor Beta SE P value Hazard ratio (95 % CI)
Age (per 10 years) 0.223 0.149 0.1295 1.25 (0.96–1.54)
Former smoker −0.193 0.054 0.0003 0.82 (0.72–0.93)
Pack years (per 10 years) 0.118 0.075 0.1125 1.13 (0.98–1.27)
Coronary calcium volume (per 500 mm3) 0.102 0.027 0.0001 1.11 (1.06–1.16)
Aortic calcium volume (per 500 mm3) 0.021 0.010 0.0423 1.02 (1.00–1.04)
Aortic valve calcium volume (per 500 mm3) 0.381 0.191 0.0430 1.46 (1.09–1.84)
Mitral valve/annulus calcium volume (per 500 mm3) 1.007 0.928 0.2718 2.74 (0.92–4.56)
Open in a new tab

Corrected for over-optimism with a correction factor of 0.988

Significant values are marked bold

An age-adjusted survival curve was evaluated by presence and absence of aortic valve calcifications (Fig. 2). The curve indicates that the presence of heart valve calcifications translates in more events. The c-statistic of a basic model with predictors proposed by Mets and colleagues [15] including age, pack years, current smoking status, coronary calcium volume and aorta calcium volume was 0.68 (95 % CI, 0.63–0.72). Adding both aortic valve and mitral valve calcium volume to this basic model resulted in a similar c-statistic of 0.68 (95 % CI, 0.64–0.73).

Fig. 2.

Fig. 2

Open in a new tab

Survival curve for aortic valve calcifications adjusted for an age category of 55–60 years

Discussion

We evaluated the prognostic value of aortic valve and mitral valve/annulus calcifications for cardiovascular events in male lung cancer screening participants without a history of cardiovascular disease. The current study showed that calcifications of the aortic valve increased cardiovascular risk by almost 50 %. However, adding cardiac valve calcium volumes did not substantially improve a model proposed by Mets et al. [15] with age, number of pack years, current smoking status, coronary calcium volume and aorta calcium volume. Therefore, assessment of cardiac valve calcifications on lung cancer screening CT examinations is not recommended for 3 years cardiovascular risk assessment if calcifications of the coronary arteries and aorta are also evaluated.

Lung cancer screening with non-gated unenhanced chest CT is primarily aimed at lung cancer detection. However, these CT examinations can also provide information about other diseases including cardiovascular diseases, especially since smoking is not only a risk factor for lung cancer, but also for cardiovascular diseases [13, 15]. The current study showed that cardiac valve calcifications were significantly more prevalent in individuals who developed a cardiovascular event compared to individuals without an event (31.7 vs 20.4 % for aortic valve calcifications and 5.9 vs 2.5 % for mitral valve/annulus calcifications, respectively). These numbers are comparable to previously reported prevalence numbers of 18–27 % for aortic valve calcifications in routine clinical care patients and an elderly population based study [8, 24, 25] and 8–9 % for mitral valve calcifications in routine clinical care patients [24, 26]. If cardiac valve calcifications were present, the volumes of these calcifications were also significantly larger in individuals who developed a cardiovascular event (179.1 vs 96.3 mm3 for aortic valve calcifications and 216.9 vs 140.8 mm3 for mitral valve/annulus calcifications, respectively). This indicates a potential prognostic value of cardiac valve calcifications in a lung cancer screening setting, which was confirmed by our multivariable cox PH regression analysis. However, cardiac valve calcification volumes do not have added predictive value after 3 years follow-up beyond age, pack years, smoking status, coronary calcium volume and aorta calcium volume. This may be explained by the relatively short follow-up time of the current study. Probably calcifications of the coronaries and the aorta are associated with cardiovascular events on the short term, whereas heart valve calcifications may be associated with more chronic diseases. Another explanation may be the etiology of cardiac valve calcifications that shares common pathways and risk factors with coronary artery calcification. Some studies indicate that calcifications of the coronary arteries, the aorta and the cardiac valves are all part of the progression of coronary atherosclerosis [27–29]. It is suggested that especially micro calcifications in the coronaries and aorta are part of the atherosclerotic pathway [30]. These may lead to plaque rupture and subsequently myocardial infarction or stroke [30]. Besides part of the atherosclerosis pathway, cardiac valve calcifications may also be a cause of valve failure [31]. Large calcifications of the aortic valve for example, may lead to impaired leaflet function followed by heart failure [30]. Calcifications of the mitral annulus are part of a chronic non-inflammatory degenerative process [32], and severe calcifications of the mitral annulus may cause mitral regurgitation [31]. Therefore, cardiac valve calcifications should be reported in the clinical radiology routine where individual risk factors may be unknown [33, 34].

The current study confirms and expands the results of Gondrie et al. [24]. They also evaluated the prognostic value of cardiac valve calcifications on future cardiovascular events. However, they evaluated a more heterogeneous routine care population with routine radiation dose chest CT exams (both with and without contrast medium) and they used a subjective assessment instead of the quantitative volume measurements as used in the current study. Gondrie et al. also found increased HRs for cardiac valve calcifications, but similar to our results cardiac valve calcifications lost their prognostic value for cardiovascular events when modelled with calcifications of the coronaries and aorta. They also had a relatively short follow-up.

An in-house developed software package was used for quantification of calcifications. Cardiac regions with Hounsfield units of 130 and higher were detected as calcium with this software package. This is similar to the validated Agatston score. However, the Agatston score was developed and validated for quantifying coronary calcifications on dedicated cardiac CT and not for cardiac valve calcifications on non-gated low-dose chest CT. Therefore, calcium quantification may be affected due to motion artifacts and worse image quality. However, newer CT systems result potentially in less artifacts and better image quality as compared to the 16-slice CT systems that are used in the current study.

Our study has limitations that should be addressed. First, despite the large sample size of the current study, only men and only (previous) smokers were included. Results may thus not be generalizable to women and non-smoking individuals. The latter is less relevant since this study is focused on additional information provided by lung cancer screening CT exams. Second, since not all Framingham risk score determinants were provided by the NELSON trial, the added value of cardiac valve calcifications beyond the Framingham risk score could not be assessed. However, we did include coronary artery calcium in our analyses, a direct measure of vascular disease, which has been proven to be a strong predictor for future cardiovascular events [35, 36], and is considered a reflection of the impact of known and unknown risk factors on the arterial wall. Third, our follow-up time was relatively short and therefore the emphasis was more on acute than on chronic disease. It may be that heart valve calcifications lead to cardiovascular events in the long term. Fourth, the NELSON lung cancer screening trial was designed and powered for lung cancer screening detection and not for cardiovascular events. Fifth, not only hard events but also soft events were included as outcome measures. Finally, the confidence interval for the HR of mitral valve/annulus calcification volumes was wider compared to aortic valve calcification volumes. This is presumably caused by the low prevalence of mitral valve/annulus calcifications (2.7 %) compared to the higher prevalence of aortic valve calcifications (21.1 %). Therefore, only a trend towards increased risk on future cardiovascular events could be evaluated for mitral valve/annulus calcifications. Moreover, van Hamersvelt et al. [18] showed that the reproducibility of mitral valve/annulus calcifications on lung cancer screening chest CT exams is not as good as for aortic valve calcifications. This may have contributed to weaker results for mitral valve/annulus calcifications as compared to aortic valve calcifications.

In conclusion, calcifications of the aortic valve are predictors for future cardiovascular events. However, there was no added prognostic value of cardiac valve calcium volumes beyond age, number of pack years, current smoking status, coronary calcium volume and aorta calcium volume for 3 years cardiovascular outcome.

Acknowledgments

Conflict of interest

The Utrecht University Medical Center department of Radiology received research support from Philips Healthcare.

Funding

None.

Abbreviations

CT

Computed tomography

C-statistics

Concordance statistics

CI

Confidence interval

NELSON

Dutch Belgian randomized lung cancer screening trial

ECG

Electrocardiography

HRs

Hazard ratios

NLST

National lung screening trial

PH

Proportional hazards

Footnotes

Clinical Trial Registration: ISRCTN63545820.

References

  • 1.Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi: 10.1056/NEJMoa1102873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Aronow WS, Ahn C, Shirani J, Kronzon I. Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol. 1999;83(4):599–600. doi: 10.1016/S0002-9149(98)00922-9. [DOI] [PubMed] [Google Scholar]
  • 3.Budoff MJ, Nasir K, Katz R, et al. Thoracic aortic calcification and coronary heart disease events: the multi-ethnic study of atherosclerosis (MESA) Atherosclerosis. 2011;215(1):196–202. doi: 10.1016/j.atherosclerosis.2010.11.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–1345. doi: 10.1056/NEJMoa072100. [DOI] [PubMed] [Google Scholar]
  • 5.Elias-Smale SE, Proenca RV, Koller MT, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol. 2010;56(17):1407–1414. doi: 10.1016/j.jacc.2010.06.029. [DOI] [PubMed] [Google Scholar]
  • 6.Iribarren C, Sidney S, Sternfeld B, Browner WS. Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA. 2000;283(21):2810–2815. doi: 10.1001/jama.283.21.2810. [DOI] [PubMed] [Google Scholar]
  • 7.Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341(3):142–147. doi: 10.1056/NEJM199907153410302. [DOI] [PubMed] [Google Scholar]
  • 8.Volzke H, Haring R, Lorbeer R, et al. Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis. 2010;209(2):606–610. doi: 10.1016/j.atherosclerosis.2009.10.030. [DOI] [PubMed] [Google Scholar]
  • 9.Wong ND, Gransar H, Shaw L, et al. Thoracic aortic calcium versus coronary artery calcium for the prediction of coronary heart disease and cardiovascular disease events. JACC Cardiovasc Imaging. 2009;2(3):319–326. doi: 10.1016/j.jcmg.2008.12.010. [DOI] [PubMed] [Google Scholar]
  • 10.Horeweg N, van der Aalst CM, Thunnissen E, et al (2013) Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med 187(8):848–854 [DOI] [PubMed]
  • 11.van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON) Int J Cancer. 2007;120(4):868–874. doi: 10.1002/ijc.22134. [DOI] [PubMed] [Google Scholar]
  • 12.Mets OM, Buckens CF, Zanen P, et al. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. JAMA. 2011;306(16):1775–1781. doi: 10.1001/jama.2011.1531. [DOI] [PubMed] [Google Scholar]
  • 13.Mets OM, de Jong PA, Prokop M. Computed tomographic screening for lung cancer: an opportunity to evaluate other diseases. JAMA. 2012;308(14):1433–1434. doi: 10.1001/jama.2012.12656. [DOI] [PubMed] [Google Scholar]
  • 14.Jacobs PC, Prokop M, van der Graaf GY, et al. Comparing coronary artery calcium and thoracic aorta calcium for prediction of all-cause mortality and cardiovascular events on low-dose non-gated computed tomography in a high-risk population of heavy smokers. Atherosclerosis. 2010;209(2):455–462. doi: 10.1016/j.atherosclerosis.2009.09.031. [DOI] [PubMed] [Google Scholar]
  • 15.Mets OM, Vliegenthart R, Gondrie MJ, et al. Lung cancer screening CT-based prediction of cardiovascular events. JACC Cardiovasc Imaging. 2013;6(8):899–907. doi: 10.1016/j.jcmg.2013.02.008. [DOI] [PubMed] [Google Scholar]
  • 16.Sverzellati N, Cademartiri F, Bravi F, et al. Relationship and prognostic value of modified coronary artery calcium score, FEV1, and emphysema in lung cancer screening population: the MILD trial. Radiology. 2012;262(2):460–467. doi: 10.1148/radiol.11110364. [DOI] [PubMed] [Google Scholar]
  • 17.Xie X, Zhao Y, de Bock GH, et al. Validation and prognosis of coronary artery calcium scoring in nontriggered thoracic computed tomography: systematic review and meta-analysis. Circ Cardiovasc Imaging. 2013;6(4):514–521. doi: 10.1161/CIRCIMAGING.113.000092. [DOI] [PubMed] [Google Scholar]
  • 18.Van Hamersvelt RW, Willemink MJ, Takx RA, et al (2014) Cardiac valve calcifications on low-dose unenhanced ungated chest computed tomography: inter-observer and inter-examination reliability, agreement and variability. Eur Radiol 24(7):1557–1564 [DOI] [PubMed]
  • 19.Isgum I, Rutten A, Prokop M, et al. Automated aortic calcium scoring on low-dose chest computed tomography. Med Phys. 2010;37(2):714–723. doi: 10.1118/1.3284211. [DOI] [PubMed] [Google Scholar]
  • 20.Isgum I, Prokop M, Niemeijer M, Viergever MA, van Ginneken B. Automatic coronary calcium scoring in low-dose chest computed tomography. IEEE Trans Med Imaging. 2012;31(12):2322–2334. doi: 10.1109/TMI.2012.2216889. [DOI] [PubMed] [Google Scholar]
  • 21.World Health Organization. International Classification of Diseases (ICD). http://www.who.int/classifications/icd/en/. Published in 2010. Accessed Jan 2013
  • 22.Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012;308(8):796–803. doi: 10.1001/jama.2012.9630. [DOI] [PubMed] [Google Scholar]
  • 23.Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156(6):438–444. doi: 10.7326/0003-4819-156-6-201203200-00006. [DOI] [PubMed] [Google Scholar]
  • 24.Gondrie MJ, van der Graaf Y, Jacobs PC, Oen AL, Mali WP. The association of incidentally detected heart valve calcification with future cardiovascular events. Eur Radiol. 2011;21(5):963–973. doi: 10.1007/s00330-010-1995-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Koos R, Kuhl HP, Muhlenbruch G, Wildberger JE, Gunther RW, Mahnken AH. Prevalence and clinical importance of aortic valve calcification detected incidentally on CT scans: comparison with echocardiography. Radiology. 2006;241(1):76–82. doi: 10.1148/radiol.2411051163. [DOI] [PubMed] [Google Scholar]
  • 26.Mahnken AH, Muhlenbruch G, Das M, et al. MDCT detection of mitral valve calcification: prevalence and clinical relevance compared with echocardiography. AJR Am J Roentgenol. 2007;188(5):1264–1269. doi: 10.2214/AJR.06.1002. [DOI] [PubMed] [Google Scholar]
  • 27.Allison MA, Cheung P, Criqui MH, Langer RD, Wright CM. Mitral and aortic annular calcification are highly associated with systemic calcified atherosclerosis. Circulation. 2006;113(6):861–866. doi: 10.1161/CIRCULATIONAHA.105.552844. [DOI] [PubMed] [Google Scholar]
  • 28.Mohler ER, III, Kaplan FS, Pignolo RJ. Boning-up on aortic valve calcification. J Am Coll Cardiol. 2012;60(19):1954–1955. doi: 10.1016/j.jacc.2012.08.961. [DOI] [PubMed] [Google Scholar]
  • 29.Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104(16):1927–1932. doi: 10.1161/hc4101.097527. [DOI] [PubMed] [Google Scholar]
  • 30.Ruiz JL, Hutcheson JD, Aikawa E (2015) Cardiovascular calcification: current controversies and novel concepts. Cardiovasc Pathol. doi:10.1016/j.carpath.2015.03.002 [DOI] [PubMed]
  • 31.Movahed MR, Saito Y, Ahmadi-Kashani M, Ebrahimi R. Mitral annulus calcification is associated with valvular and cardiac structural abnormalities. Cardiovasc Ultrasound. 2007;5:14. doi: 10.1186/1476-7120-5-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Nemcsik J, Farkas K, Kolossvary E, et al. Intracardiac calcification is a marker of generalized atherosclerosis. Angiology. 2007;58(4):413–419. doi: 10.1177/0003319706291112. [DOI] [PubMed] [Google Scholar]
  • 33.Gondrie MJ, Mali WP, Jacobs PC, Oen AL, van der Graaf Y. Cardiovascular disease: prediction with ancillary aortic findings on chest CT scans in routine practice. Radiology. 2010;257(2):549–559. doi: 10.1148/radiol.10100054. [DOI] [PubMed] [Google Scholar]
  • 34.Jairam PM, Gondrie MJ, Grobbee DE, Mali WP, Jacobs PC, van der Graaf Y. Incidental imaging findings from routine chest CT used to identify subjects at high risk of future cardiovascular events. Radiology. 2014;272(3):700–708. doi: 10.1148/radiol.14132211. [DOI] [PubMed] [Google Scholar]
  • 35.Johnson KM, Dowe DA, Brink JA. Traditional clinical risk assessment tools do not accurately predict coronary atherosclerotic plaque burden: a CT angiography study. AJR Am J Roentgenol. 2009;192(1):235–243. doi: 10.2214/AJR.08.1056. [DOI] [PubMed] [Google Scholar]
  • 36.Johnson KM, Dowe DA. The detection of any coronary calcium outperforms Framingham risk score as a first step in screening for coronary atherosclerosis. AJR Am J Roentgenol. 2010;194(5):1235–1243. doi: 10.2214/AJR.09.2487. [DOI] [PubMed] [Google Scholar]

Articles from The International Journal of Cardiovascular Imaging are provided here courtesy of Springer

RESOURCES